Savara, Inc. · NASDAQ:SVRA
Savara — Technical Presentation (September 2026)
11 slides from Savara's technical presentation, Sep 6, 2026
Slide 1: Molgramostim for Autoimmune Pulmonary Alveolar Proteinosis: IMPALA-2 Open-Label Results
Molgramostim for the Treatment of Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP): Long-term Efficacy and Safety Results from the Open- Label Period of the IMPALA-2 Phase 3 Clinical Trial Bruce C. Trapnell,1 Yoshikazu Inoue,2,3 Francesco Bonella,4 Cormac McCarthy,5 Tisha Wang,6 Ali At
Slide 2: Financial Disclosures
Financial Disclosures • I (BCT) have received grants or contracts from the National Institutes of Health. • I have been a consultant for Partner Therapeutics and Savara Inc. • I have an unpaid role as a Scientific Director and Board Chairman at the PAP Foundation. • The IMPALA-2 clinical trial is sp
Slide 3: Autoimmune Pulmonary Alveolar Proteinosis (aPAP): Pathogenesis
Autoimmune Pulmonary Alveolar Proteinosis (aPAP): Pathogenesis Molgramostim inhalation solution is a recombinant human GM-CSF in development for the treatment of aPAP GM-CSF, granulocyte-macrophage colony-stimulating factor.
Slide 4: IMPALA-2: Phase 3 Clinical Trial of Molgramostim in aPAP
IMPALA-2: Phase 3 Clinical Trial of Molgramostim in aPAP Screening/Observation Double-blind Treatment Period Open-label Treatment Period • DLCO ≤70% predicted at first Molgramostim 300 μg once daily screening and baseline • Change in % predicted DLCO Molgramostim 300 μg once daily <15% points to ens
Slide 5: IMPALA-2 Patient Disposition
IMPALA-2 Patient Disposition Screened (n=286) Ineligible (n=122) Randomized (N=164) Molgramostim Placebo Treatment Treatment (n=81) (n=83) discontinued discontinued (n=2) (n=3) • 2 AEs* • 1 AE* 97.5% Completed 96.4% Completed • 1 Pregnancy double-blind period (n=79) double-blind period (n=80) • 1 Lo
Slide 6: DLCO% Improved Through Week 96 with Continued Molgramostim and Increased After Placebo Crossover
DLCO% Improved Through Week 96 with Continued Molgramostim and Increased After Placebo Crossover* Molgramostim/Molgramostim 79 74 71 74 77 77 75 77 76 70 77 75 Placebo/Molgramostim 81 77 78 82 79 81 82 78 77 77 72 71 *Arithmetic mean changes from baseline for observed data. DLCO%, percent predicted
Slide 7: SGRQ Total Score Improved Through Week 96 with Continued Molgramostim and After Placebo Crossover
St. George’s Respiratory Questionnaire (SGRQ) Total Score Improved Through Week 96 with Continued Molgramostim and After Placebo Crossover* Molgramostim/Molgramostim 72 72 72 71 71 72 70 71 70 70 72 71 Placebo/Molgramostim 76 76 73 76 74 75 75 76 75 76 74 72 *Arithmetic mean changes from baseline fo
Slide 8: SGRQ Activity Score Improved Through Week 96 with Continued Molgramostim and After Placebo Crossover
St. George’s Respiratory Questionnaire (SGRQ) Activity Score Improved Through Week 96 with Continued Molgramostim and After Placebo Crossover* Molgramostim/Molgramostim 72 72 72 71 71 72 70 71 70 70 72 71 Placebo/Molgramostim 76 75 73 75 74 75 75 76 75 76 74 72 *Arithmetic mean changes from baseline
Slide 9: No Treatment-Related Discontinuations Through Week 96; Safety Consistent with Double-Blind Period
No Treatment-Related Discontinuations Through Week 96; Safety Consistent with the Double-Blind Period* MOL-MOL PBO-MOL MOL-MOL PBO-MOL Treatment-Emergent AEs Treatment-Emergent AEs n=79 (%) n=81 (%) n=79 (%) n=81 (%) Any adverse event 72 (91) 70 (86) Most common (>10% of patients in either treatment
Slide 10: Conclusions (IMPALA-2 Open-Label Treatment Period)
Conclusions (IMPALA-2 Open-Label Treatment Period) Long-term treatment with molgramostim continuously improved pulmonary gas transfer and respiratory health-related quality of life (HRQoL) in aPAP patients After crossing over to molgramostim in the open-label period, placebo patients experienced
Slide 11: Thank you!
Thank you! We thank our patients and the investigators who participated in the IMPALA-2 trial